Continuing Medical Education (CME) Performance Measures
Cutting Edge Information's latest research study shows that pharmaceutical companies are still apprehensive to begin tracking the performance and effectiveness of their medical education efforts (http://www.CMEPharma.com).
Much of the industry is still skittish about violating anti-kickback laws or about failing to adhere to the guidelines set forth by the Accreditation Council for Continuing Medical Education (ACCME), which are designed to ensure that the industry's medical education investments remain independent from commercial bias. The report found that as companies become more comfortable operating in the new compliance environment, they become more willing to track hard goals. In fact, a minority of companies consulted in Cutting Edge Information's research indicated that they are considering putting some basic annual objectives in place within by 2008.
"Pharmaceutical CME: Measuring Program Effectiveness in the Compliance Environment," available at (http://www.CMEPharma.com) is designed to evaluate pharmaceutical CME departments' current strategies, best practices, performance measurement systems and resource allocation trends. The report uncovers key findings and innovative solutions from leading pharmaceutical and biotechnology companies, including Novartis, Sanofi-Aventis, TAP Pharmaceutical and Amgen.
"Performance measurement is a sticky subject when you're talking about CME," said Elio Evangelista, senior analyst at Cutting Edge Information. "But to justify the industry's huge expense when supporting continuing medical education, pharma companies will want to know how effectively their investments are building disease awareness."
The study shows that only 24% of participating pharmaceutical companies track return on investment for their CME activities. Tracking CME performance does not have to interfere with the industry's altruistic investments in medical education events. For example, one profiled company conducts randomized control trials to test the impact of educational events on physician behaviors, including prescribing habits.
"Pharmaceutical CME: Measuring Program Effectiveness in the Compliance Environment" is the most comprehensive study on the state of CME in the pharmaceutical industry today. The report provides solutions to the top challenges faced by CME departments on a daily basis, including:
- Performance measurement
- Grants process standardization and improvement
- The effect of compliance guidelines on CME strategy
- Structural separation between commercial and medical operations
Article Source: http://www.content.onlypunjab.com
|
